Change of Adviser

Oxford Biomedica PLC
03 October 2005


FOR IMMEDIATE RELEASE                                            3 OCTOBER 2005

                   OXFORD BIOMEDICA ANNOUNCES APPOINTMENT OF
                      EVOLUTION SECURITIES AS SOLE BROKER

Oxford, UK: 3 October 2005 - Oxford BioMedica (LSE: OXB.L), the leading gene
therapy company, today announces that it has appointed Evolution Securities
Limited as its sole broker.

                                    - Ends -

For further information, please contact:
                                                        
Oxford BioMedica plc:                     Tel: [phone]

Professor Alan Kingsman, Chief Executive
City/Financial Enquiries:                 Tel: [phone]

Lisa Baderoon/ Mark Court/ Mary-Jane Johnson
Buchanan Communications

Scientific/Trade Press Enquiries:         Tel: [phone]
Sue Charles/ Katja Stout/ Ashley Lilly
Northbank Communications

Notes to editors

Oxford BioMedica
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the
development of novel gene-based therapeutics with a focus on the areas of
oncology and neurotherapy. The Company was established in 1995 as a spin out
from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house
clinical, regulatory and manufacturing know-how. In oncology, the pipeline
includes an immunotherapy and a gene therapy in multiple Phase II trials, and a
preclinical targeted antibody therapy in collaboration with Wyeth. In
neurotherapy, the Company's lead product is a gene therapy for Parkinson's
disease, which is expected to enter clinical trials in 2006, and four further
preclinical candidates. The Company is underpinned by over 80 patent families,
which represent one of the broadest patent estates in the field.

The Company has a staff of approximately 65 split between its main facilities in
Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Viragen,
MolMed and Kiadis; and has licensed technology to a number of companies
including Merck & Co, Biogen Idec and Pfizer.

Further information is available at http://www.oxfordbiomedica.co.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange